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Abstract
Background:  The C-terminal binding protein 1 (CtBP1) is a known co-repressor of gene
transcription. We recently revealed that CtBP1 expression is lost in melanoma cells and melanoma
inhibitory activity (MIA) expression is subsequently increased. The present study was performed
to evaluate a more general role of CtBP1 in human melanoma and identify further CtBP1-regulated
target genes.
Methods: Sequence analysis and expression profile of CtBP1 in melanoma cell lines were done by
PCR. Boyden Chamber assays and co-immunoprecipitation were performed to investigate the
functional role of CtBP1. Gene expression analysis and micro array data were used to define target
genes.
Results: Interestingly, we detected an alternative splice product of CtBP1 with unknown function
whose expression is induced at reduction of full length CtBP1. Overexpression of full length CtBP1
in melanoma cells had no effect on cell proliferation but did influence cell migration and
invasiveness. To understand the effect of CtBP1 we identified putative LEF/TCF target genes found
to be strongly expressed in melanoma using DNA microarray analysis. We focused on fourteen
genes not previously associated with melanoma. Detailed analysis revealed that most of these were
known to be involved in tumor metastasis. Eleven genes had expression profiles associated with
melanoma cell invasiveness.
Conclusion: In summary, this study revealed that reduction of CtBP1 expression is correlated
with migratory, invasive potential of melanoma cells.
Background
CtBP1 was first identified as a cytoplasmatic protein
which binds the COOH-terminal region of the adenoviral
protein E1A to attenuate its ability to activate transcrip-
tion. CtBP1 recognizes PXDLS and RRT motifs in DNA-
binding proteins and functions as a transcriptional co-
repressor in Drosophila, Xenopus, and mammals. CtBP1
contains a central NAD(H)-binding domain and exhibits
a weak dehydrogenase activity. This domain is also impor-
tant for dimerization of CtBP1 contributing to the recruit-
ment of transcriptional regulators. Recent studies revealed
that the repressor function of CtBP1 is mediated by bind-
ing to enzymes catalyzing histone modification as class 1
HDACs (for review see [1]). A number of studies have pro-
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vided evidence that CtBP1 binds to and regulates HMG-
box proteins as TCF4 [2] implicating them in context-
dependent transcriptional repression. Transcription fac-
tors of the LEF/TCF family contain a homologous HMG-
box, recognizes a conserved consensus sequence and reg-
ulates expression of genes also involved in melanoma
development [3]. In previous work we could show that
CtBP1 functions as a strong repressor of melanoma inhib-
itory activity (MIA) expression by negatively regulating
MIA promoter activity in malignant melanoma, and that
this repressor function requires the TCF binding element
in the MIA promoter [4]. Expression of MIA is an early
event in melanoma development and correlates with
tumor progression in vivo. MIA promotes invasion and
metastasis of melanoma cells regulating cell-matrix
attachment (for review see [5]).
CtBPs has a wide impact in tumorigenesis interacting with
transcriptional repressors influencing oncogenic and pro-
survival pathways (for review see [6]). It was previously
shown that CtBP interacts with Snail contributing to
tumor progression [7,8]. Further analyses revealed CtBP1
to be strongly expressed in primary melanocytes whereas
in melanoma cells in vitro and in vivo full length CtBP1
expression is lost or strongly downregulated suggesting an
important role of CtBP1 in melanoma progression [3]. To
define the role of CtBP1 in melanoma more clearly we
performed a screening for CtBP1 target genes.
Methods
Cell culture
The melanoma cell lines Mel Im hi, Mel Im si, Mel Im, Mel
Ju, Mel Juso, Mel Ho, Mel Ei, Mel Wei, Sk Mel 3, Sk Mel 28
and HTZ 19d were described previously [9,10]. Cells were
maintained in DMEM supplemented with penicillin (400
U/ml), streptomycin (50 μg/ml), L-glutamine (300 μg/
ml) and 10% fetal calf serum (FCS; Sigma, Deisenhofen,
Germany) and split at a 1:5 ratio every three days. Normal
human epidermal melanocytes (NHEM) derived from
normal skin were cultivated in melanocyte medium
MGM-3 (Promocell, Heidelberg, Germany) under a
humidified atmosphere of 5% CO2 at 37°C. Cell prolifer-
ation was determined using the XTT assay (Roche, Man-
nheim, Germany).
A panel of Mel Im cell clones with CtBP1 expression was
established by stable transfection using a pCMX-PL1-
CtBP1 expression plasmid [4]. Plasmids were cotrans-
fected with pcDNA3 (Invitrogen), containing the selecta-
ble marker for neomycin resistance. Mock controls
received pcDNA3 alone. Transfections were performed
using lipofectamin plus (Invitrogen). One day after trans-
fection, cells were placed in selection medium containing
50 μg/ml G418 (Sigma). After 25 days of selection, indi-
vidual G418-resistant colonies were subcloned.
RNA isolation and reverse transcription
Total cellular RNA was isolated from cultured cells (4 ×
106). cDNAs were generated by reverse transcriptase reac-
tion performed in 20 μl reaction volume containing 2 μg
of total cellular RNA, 4 μl of 5× first strand buffer (Invit-
rogen, Groningen, The Netherlands), 2 μl of 0.1 M DTT, 1
μl of dN6-primer (10 mM), 1 μl of dNTPs (10 mM) and
DEPC-water. The reaction mixture was incubated for 10
min at 70°C, 200 units of Superscript II reverse tran-
scriptase (Invitrogen) were added and RNAs were reverse
transcribed for 1 hour at 37°C. Reverse transcriptase was
inactivated at 70°C for 10 minutes and the RNA was
degraded by digestion with 1 μl RNase A (10 mg/ml) at
37°C for 30 minutes. The quality of cDNA was controlled
and normalized by RT-PCR amplification of the house
keeping gene β-actin.
Analysis of gene expression
Quantitative real time-PCR was performed on a Lightcy-
cler (TaKaRa, Bio, USA). cDNA template (2 μl), 0.5 μl (20
mM) of forward and reverse primers (Table 1) and 10 μl
of SYBR Premix Ex Taq in a total of 20 μl were applied to
the following PCR program: 10 min 95°C (initial dena-
turation); 20°C/sec temperature transition rate up to
95°C for 15 sec, 3 sec 64°C, 5 sec 72°C, 86°C acquisition
mode single, repeated for 40 times (amplification). Each
analysis was performed at least in triplicate. The PCR reac-
tion was evaluated by melting curve analysis according to
the manufacturer's instruction and checking the PCR
products on 1.8% agarose gels. The quality of cDNA was
controlled and normalized by RT-PCR amplification of
the house keeping gene β-actin.
For further analysis of gene expression, we used the micro
array data of Smith et al. (GDS1989 [11]) and Hoek et al.
[12]. Via Pigment Cell & Melanoma Research Homepage
http://www.pigment.org/genearray_home.asp, these data
are available for public.
Sequence analysis of the splice donor and splice acceptor
site of CtBP exon 4 was performed on a DNA fragment
amplified by conventional PCR using the primers CtBP1
Exon4 for: 5'-TTC AAA CCC GCT CCA GTC-3' and CtBP1
Exon4 rev: 5'-TCA GTC CTG TCC TGG GT TG-3'.
Western Blot analysis
3 × 106 cells were lysed in 200 μl RIPA-buffer (Roche) and
incubated for 15 minutes at 4°C. Insoluble fragments
were removed by centrifugation at 13000 rpm for 10 min-
utes and the supernatant lysate was immediately shock
frozen and stored at -80°C. 40 μg RIPA-cell lysate of each
sample of melanoma cell lines were loaded and separated
on 8.75% SDS-PAGE gels and subsequently blotted onto
a PVDF membrane (1 hour, 150 mA). After blocking for 1
hour with 3% BSA/PBS the membrane was incubated forBMC Cancer 2009, 9:52 http://www.biomedcentral.com/1471-2407/9/52
Page 3 of 11
(page number not for citation purposes)
16 hours with the primary antibody (anti-CtBP1 anti-
body, Transduction Lab, 1:2500) or beta-actin (Sigma,
1:2500). Then the membrane was washed three times in
PBS, incubated for 1 hour with 1:4000 of an alkaline
phosphate-coupled secondary antibody (Chemicon) and
then washed again. Finally immunoreactions were visual-
ized by NBT/BCIP (Sigma) staining.
Co-Immunoprecipitation (Co-IP)
For co-immunoprecipitation cell lysates dissolved in
binding buffer (20 mM NaPO4, 150 mM NaCl, pH 7.5)
were incubated with 2 μg of the anti-TCF4 [4] or anti-Snail
antibody (Cell Signaling, USA) with shaking at 4°C over-
night. Then 20 μl protein G Sepharose 4 Fast Flow (Amer-
sham, Biosciences) was added for 1 h, pelleted, washed
three times with binding buffer, resuspended in 20 μl of
Laemmli's buffer, heated at 95°C for 5 min, separated on
10% SDS-polyacrylamide gels and subsequently blotted
onto a PVDF membrane (1 hour, 150 mA). After blocking
for 1 hour with 3% BSA/PBS the membrane was incu-
bated for 16 hours with the primary antibody (anti-CtBP1
antibody (1:2500)). Then the membrane was washed
three times in PBS, incubated for 1 hour with 1:2000 of an
alkaline phosphate-coupled secondary antibody (Chemi-
con) and then washed again. Finally, immunoreactions
were visualized by NBT/BCIP (Sigma) staining.
Migration and invasion assay
Migration and invasion assays were performed using
Boyden Chambers containing polycarbonate filters with 8
μm pore size (Costar, Bodenheim, Germany), essentially
as described previously [13]. Filters were coated with gel-
atine or Matrigel (diluted 1:3 in H2O; Becton Dickinson,
Heidelberg, Germany), respectively. The lower compart-
ment was filled with fibroblast-conditioned medium,
used as a chemo-attractant. Mel Im cells and CtBP1 cell
clones were harvested by trypsinization for 2 min, resus-
pended in DMEM without FCS at a density of 3 × 104 cells/
ml (migration) and 2 × 105 cells/ml (invasion) and placed
in the upper compartment of the chamber. After incuba-
tion at 37°C for 4 hours, the filters were collected and the
cells adhering to the lower surface fixed, stained and
counted. Each assay was repeated at least three times.
Statistical analysis
Results are expressed as mean ± SD (range) or percent.
Comparison between groups was made using the Stu-
dent's unpaired t-test. A p value < 0.05 was considered sta-
tistically significant. All calculations were performed
using the GraphPad Prism software (GraphPad software
Inc, San Diego, USA).
Results
Recently, we showed that CtBP1 expression is lost or
strongly reduced in malignant melanoma leading to
induction of MIA expression [4]. To find cellular mecha-
nisms regulated by CtBP1 in melanoma we generated
CtBP1 expressing melanoma cells by stable transfection to
subsequently perform functional assays. The three cell
clones selected show strong CtBP1 mRNA and protein
expression (Fig. 1A). To confirm the regulation of MIA
expression we performed quantitative RT-PCR and
revealed a significant reduction of MIA expression in the
CtBP1-expressing cell clones compared to mock controls
(Fig. 1B). Proliferation and colony formation assays
showed no difference in cell growth between CtBP1
expressing and the control clones (data not shown). In
contrast, reduction of migration (Fig. 2A) and invasion in
Boyden Chamber assays (Fig. 2B) was observed suggesting
that CtBP1 and CtBP1-regulated genes control cellular
migration.
Interestingly, we observed a second minor signal in West-
ern blotting, using the anti-CtBP1 antibody, approxi-
Table 1: Primers used for quantitative RT-PCR
Gene name for rev
AP1S1 GGAGGAGATGGGTTTGGCAT GTGGAGGGAGGGAATGTTTGA
ATP1B1 TGGCTGGCATCTTCATCGGA CTTTCGGTTCACTGGGCACA
CLDN11 TCTGTTGCTCAGGCTGGAGT CGAGGCGGGAGGATACTTTGA
COL1A2 CCCAGCCGGAGATAGAGG TCACCAGGCTCACCAGCAGG
CtBP1 CGACCTCCGATCATGAAC GCTAAAGCTGAAGGGTTCC
ENC1 GCAACTTCCAAACCATCAGGA TCTGGGAGGTAGCAATAGCG
ENPP2 GGAGAGTCGCATTGGGTTGA TGTAGGGAGAGTGTGTGCCA
FAT CCAATGATAATCCACCCGAGTT TAACAACACCCGTCACGC
FSCN1 CCTGGGCGTGTAGTGTAACT CACCACAAGGGTCAGTCCTA
FUS TTCGTTGCTTGCTTGCCTG TGTAACTCTGCTGTCCGTAGG
MLL5 TGGGCTTGTATCTGGTTTCGG CTGGTGTTGGTAAAGGTAGGCTA
SLC26A2 GATTGGTGAGACAGTTGACCG TTGAAAGAAGCCCATCGCTAC
THBS1 ACTGCGTTGGTGATGTAACAG GTGCTCTCCATTGTGGTTGAA
TMED4 TGGGATAAGCAGAAGGAGGTC ATCTCAGGGTAGTTGTTGGCA
VCAN TCAGAACAGCAAGTGGCAGCGA CAACACAAGTGGCTCCATTACGACBMC Cancer 2009, 9:52 http://www.biomedcentral.com/1471-2407/9/52
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CtBP1 re-expressing melanoma cell clones Figure 1
CtBP1 re-expressing melanoma cell clones. An expression plasmid for CtBP1 was introduced into Mel Im cells by stable 
transfection. (A) Expression of CtBP1 protein was analyzed by western blotting. Expression of full length CtBP1 was observed 
in the CtBP1-transfected cell clone CtBP1#3, CtBP1#6 and CtBP1#8 but not in the wild-type Mel Im cell line or in the mock 
transfected cell clones Mock 1 and Mock 2. (B) Influence of CtBP1 expression on MIA mRNA expression was determined by 
quantitative RT-PCR. The three CtBP1 re-expressing clones (CtBP1#3, #6 and #8) showed strong reduction in MIA expres-
sion compared with mock transfected clones. (*: p < 0.05 compared to Mock 1).BMC Cancer 2009, 9:52 http://www.biomedcentral.com/1471-2407/9/52
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Migration and invasion in CtBP1 expressing cell clones Figure 2
Migration and invasion in CtBP1 expressing cell clones. The migratory and invasive potential of the cells was assessed 
by Boyden Chamber assays using the CtBP1 expressing cell clones. Here, strong reduction in migration (A) and invasion (B) 
was observed after CtBP1 re-expression in all three cell clones in comparison to control cells. (*: p < 0.05 compared to Mock 
2).BMC Cancer 2009, 9:52 http://www.biomedcentral.com/1471-2407/9/52
Page 6 of 11
(page number not for citation purposes)
mately 5 kDa smaller than full length CtBP1 (RefSeq entry
NM_001328) (Fig. 1A). To determine whether this band
is due to an alternative splice product of CtBP1 we
designed several sets of primer. Using these PCR primers
and subsequent sequencing we show that melanoma cells
express an alternative CtBP product lacking exon 4
(CtBP1splice) (Fig. 3A, B). Sequence analysis of genomic
DNA revealed no mutations in splice sites causing the
skipping of exon 4 in melanoma. The expression pattern
of CtBP1splice in melanoma is demonstrated in Fig. 3A
and revealed the expression of the splice variant in eight
of eleven melanoma cell lines. The downregulation of full
length CtBP1 in melanoma was previously shown [4].
This results in a protein missing aa 114–182, which is the
N-terminal region of the dehydrogenase homology
domain and includes a PAK1 phosphorylation site (Fig.
3C). As the nature of this alternative splice product is
completely unknown, we sought to determine whether
CtBP1 binding to TCF4 (which regulates MIA expression)
and Snail is intact. By co-immunoprecipitation we
detected TCF4 and Snail binding to full length CtBP1 (in
the CtBP1-expressing melanoma cell clones), but none
with CtBP1splice (Fig. 4A, B). This suggests that
CtBP1splice can not modulate repressor activity on TCF4
and Snail, although other CtBP1 functions may be unaf-
fected.
CtBP1 target genes
As full length CtBP1 expression is lost in melanoma we
hypothesized that CtBP1 acts as a tumor suppressor by
negatively regulating genes involved in melanoma devel-
opment and progression. As CtBP1 is a known repressor
of LEF/TCF signaling we first concentrated on known LEF/
TCF target genes. MMP7 was found to be down regulated
5-fold by CtBP1 in melanoma, whereas c-myc and lam-
inin gamma 2 were not affected. To define novel putative
LEF/TCF target genes in melanoma we screened for genes
with LEF/TCF binding sites (TT/GCTTTG) in their pro-
moter using Genomatix software. Genes were chosen
showing at least one LEF/TCF binding site as these may be
activated if repression by CtBP1 is lost in melanoma and
wnt signaling is activated. These genes were analyzed
using GEO Profiles (NCBI) in the melanoma array data
GDS1989 [11] and we concentrated on genes found to be
upregulated during development or progression of the
disease. Fourteen of 250 genes analyzed were observed to
fit the criteria (LEF/TCF binding site and upregulated in
melanoma) applied (table 2). Regulation by CtBP1 of the
genes chosen was tested by quantitative RT-PCR in the
CtBP1-expressing cell clones compared to the mock con-
trol (table 2). Repression of gene expression by CtBP1 was
observed in all but two genes (THBS1, MLL5). Col1A2,
FAT, SLC26A2 and VCAN were shown to be most strongly
regulated. Downregulation of these genes by CtBP1 was
confirmed by transient transfection of CtBP1 into the
melanoma cell line (Col1A2: 0.31, FAT: 0.52, SLC26A2:
0.72, VCAN: 0.75 compared to mock control set as 1).
To get more information about the relevance of the genes
found to be regulated by CtBP1 for malignant melanoma
we used DNA microarray data obtained from proliferative
and invasive phenotype cultures [12]. This showed that
expression of 11 CtBP1-regulated genes (73%) were sig-
nificantly associated with the invasive phenotype recently
characterized by Hoek et al. [12] and none with the prolif-
erative cluster supporting our functional data that CtBP1-
regulated genes control cellular migration (table 2).
Discussion
CtBP1 is a known co-repressor involved in gene regula-
tion with several other transcription factors. Recently, we
described the loss of CtBP1 expression in melanoma [4].
In this study, we aimed to evaluate the importance of this
loss and subsequent changes to regulated genes in more
detail.
Interestingly, Western blot and RT-PCR studies revealed
the existence of a CtBP1 splice variant (CtBP1splice) in
melanoma cells. This variant lacks exon 4 (in frame) lead-
ing to a CtBP1 variant missing aa 114–182, and does not
bind TCF4 or Snail suggesting that CtBP1 co-repressor
activity may not be fulfilled by this variant. However,
CtBP1 splice product in melanoma cells Figure 3
CtBP1 splice product in melanoma cells. As observed 
in Fig. 1A a smaller CtBP1 splice variant is expressed in 
melanoma cells. (A) Using primers flanking the region coded 
by exon 4 revealed lack of exon 4 in the melanoma cell line 
Mel Im in comparison to normal human melanocytes 
(NHEM). The expression of CtBP1splice was shown in eight 
of eleven melanoma cell lines using PCR (B) Sequence analy-
sis of the PCR product shown in (A) confirmed lack of the 
coding region represented by exon 4. (C) In a schematic 
drawing localization of exon 4 of CtBP1 is displayed.BMC Cancer 2009, 9:52 http://www.biomedcentral.com/1471-2407/9/52
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expression of the variant seems to be important in tumors
as CtBP1splice was also detected in breast, colon and
hepatocellular carcinoma cells which lack full length
CtBP1 expression (data not shown). Several other splice
forms of CtBP1 have been previously detailed [14], how-
ever the splice variant we describe is novel. The lack of the
PAK phosphorylation site could lead to changes in the
control of nuclear-to-cytosolic translocation and co-
repressor function [15]. In addition, NAD binding to
CtBP1 and CtBP1 dimerization may be affected. As
NAD(H)-dependent dimerization is required for tran-
scriptional repression, repressor functions could also be
influenced. Additionally, changes in the two protein bind-
ing sites could impact the binding of transcription factors
to CtBP1splice [16,17]. CtBP1splice expression after
reduction of full length CtBP1 could be important in
tumor cells due to general functions recently been
described for CtBP as CtBP1 was shown to be involved in
Golgi morphogenesis by association to centrosomes [18]
and in vesicular trafficking. Interestingly, some publica-
tions also hint at a role for CtBP as a tumor promoter [1].
Jin et al. describe upregulation of MDR1 by CtBP1 leading
to drug resistance [19]. This effect could not be shown to
be modulated by histone modification which led the
authors to suggest regulation via CtBP1 by an unknown
mechanism. In addition, CtBP1 was shown to activate
expression of Wnt genes in a TCF-independent manner
[20]. It can only be speculated that these tumor promot-
ing effects can be achieved by CtBP1splice. Further studies
are necessary to understand the function and role of
CtBP1splice in carcinogenesis.
CtBP1 has been speculated to be involved in normal cell
growth control. It was shown previously that the binding
of CtBP to adenoviral E1A correlates with inhibition of
E1A and H-ras cotransformation, tumorigenesis, and
metastasis [21]. Furthermore, a repressor function of CtBP
on E2F-medited transcription via RB was detected [22]. In
CtBP1splice does not interact with TCF4 and Snail Figure 4
CtBP1splice does not interact with TCF4 and Snail. Co-immunoprecipitation were performed using protein lysates of 
Mel Im Mock 1 control transfected cells and the CtBP1#3 cell clones and were incubated with TCF4-antibody (A) or Snail-anti-
body (B). Western blotting with CtBP1-antibody confirmed binding of full length CtBP1 to TCF4 (A) and Snail (B), respec-
tively, whereas CtBP1splice could not interact with these proteins.B
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Table 2: Details on genes regulated by CtBP1 associated to melanoma development Genes with TCF/LEF binding sites in their promoter were analyzed.
Gene symbol Gene name TCF/LEF site GDS1989 [xfold ind., Nevus set as 1] [11] CtBP1 clones 
versus mock
Hoek et al. [12] x fold ind. P <
MIS RGP LN met prol. inv.
AP1S1 adaptor-related 
protein complex 
1. sigma 1 subunit
+ 2.02 2.99 5.23 0.77 0.99 1.10 1.11 ns
ATP1B1 ATPase. Na+/K+ 
transporting. beta 
1 polypeptide
+ 3.11 3.89 2.63 0.77 1.01 2.05 2.03 ns
CLDN11 claudin 11 
(oligodendrocyte 
transmembrane 
protein)
+ 1.06 5.15 2.30 0.67 1.97 128.6 65.38 0.003
COL1A2 collagen type I 
alpha 2
+ 1.01 2.90 2.00 0.38 6.25 34.62 5.54 0.005
ENC1 ectodermal-neural 
cortex (with BTB-
like domain)
+ 2.58 13.19 14.38 0.68 0.69 2.66 3.88 0.003
ENPP2 ectonucleotide 
pyrophosphatase/
phosphodiesteras
e 2 (autotaxin)
+ 0.86 1.36 2.31 0.66 1.40 4.43 3.17 0.047
FAT FAT tumor 
suppressor 
homolog 1 
(Drosophila)
+ 1.29 2.65 3.29 0.52 0.85 1.66 1.95 0.004
FSCN1 fascin homolog 1. 
actin-bundling 
protein 
(Strongylocentrot
us purpuratus)
+ 2.07 4.36 3.21 0.79 0.75 2.77 3.67 0.0002B
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FUS fusion (involved in 
t(12;16) in 
malignant 
liposarcoma)
+ 1.70 2.59 3.29 0.82 1.31 0.94 0.71 0.039
MLL5 myeloid/lymphoid 
or mixed-lineage 
leukemia 5 
(trithorax 
homolog. 
Drosophila)
+ 1.77 3.43 3.91 1.32 1.22 1.03 0.85 ns
SLC26A2 solute carrier 
family 26 (sulfate 
transporter). 
member 2
+ 1.86 4.8 3.11 0.41 1.20 1.87 1.56 ns
THBS1 thrombospondin 1 + 1.28 5.91 3.61 1.2 0.27 13.59 49.87 9.46E-06
TMED4 transmembrane 
emp24 protein 
transport domain 
containing 4
+ 0.81 1.75 1.99 0.74 0.91 1.73 1.89 0.002
VCAN versican + 0.88 3.02 4.53 0.42 0.73 15.43 21.24 0.0001
Using the micro array data GDS1989 [11] upregulation of these genes during melanoma development and progression is shown in columns 4 to 6. The regulation of these genes by CtBP1 was quantified in 
CtBP1 expressing cell clones by real time-PCR (column 7). For analysis of the proliferative and invasive phenotype the data of Hoek et al. [12] were used (column 8, 9). P-value < 0.05 was printed in bold. 
Abbreviations: MIS, melanoma-in-situ; RGP, radial growth phase; LN met, lymph node metastasis; prol., proliferative phenotype; inv., invasive phenotype.
Table 2: Details on genes regulated by CtBP1 associated to melanoma development Genes with TCF/LEF binding sites in their promoter were analyzed. (Continued)BMC Cancer 2009, 9:52 http://www.biomedcentral.com/1471-2407/9/52
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our study, proliferation was unchanged after reexpression
of CtBP1 whereas migration and invasion assays pointed
to a role of CtBP1 in cell migration as reexpression of
CtBP1 induced a reduction of the migratory potential.
This finding was further supported by detailed analysis of
CtBP1-regulated genes. By comparison of genes carrying a
LEF/TCF site with cDNA array data (GDS1989) [11] on
melanoma fourteen genes showing a correlation with
melanoma development and progression were deter-
mined. Regulation of these genes by CtBP1 was confirmed
performing quantitative RT-PCR. Interestingly, expression
of most CtBP1-regulated genes discussed here is associ-
ated with the invasive state recently described by Hoek
and co-workers [12]. This supports the finding that loss of
CtBP1 enhances the migratory behavior of cells.
Only two of the CtBP1-regulated genes were previously
described as playing a role in melanoma. ENPP2 (Auto-
taxin) was originally isolated from melanoma cells and
shown to augment the invasive potential of melanoma
cells by inducing uPA expression [23,24]. Versican was
also previously described to be expressed in melanoma
and to be an inducer of metastasis [25]. The remaining
genes have not previously been described to play a role in
melanoma, however, deregulation and implication in
other kinds of cancer has been noted. ATP1B1, an Na2K-
ATPase, was found to be involved in progression and
metastasis of prostate cancer [26]. Collagen type I alpha2
and FUS were found to be deregulated in gastric cancer
and speculated to play a role in invasion and metastasis
[27]. Changes in Claudin 11 were shown during progres-
sion of epithelial tumors leading to acquisition of migra-
tory potential [28]. Upregulation of ENC1, an actin-
binding protein, contributes to colorectal carcinogenesis
[29]. Regulation of ENC1 gene expression by LEF/TCF was
already shown. FAT, a cadherin-family molecule, and
FCSN1, a protein involved in the assembly of actin fila-
ment bundles, were described to play a role in general cell
migratory processes [30,31]. Enhanced FSCN1 expression
was associated with increased invasiveness in urinary can-
cer. TMED4 was significantly induced in invasive adeno-
carcinoma [32]. In summary, the data available on the
functional role of CtBP1-regulated genes hint to an impli-
cation in migratory and invasive processes.
It therefore appears that loss of the CtBP1 co-repressor
function may be a critical event in the pathogenesis of
melanoma. In future, it would be highly interesting to
extend the analysis and perform in vivo analysis to look at
effects of full length CtBP1 upon tumor growth in a nude
mouse model.
Conclusion
In melanoma cells loss of full length CtBP1 expression, a
known co-repressor involved in gene regulation with sev-
eral other transcription factors, is accompanied by induc-
tion of a CtBP1 splice variant. This variant lacks exon 4 (in
frame) leading to a CtBP1 variant which is unable to bind
TCF4 or Snail suggesting that CtBP1 co-repressor activity
may not be fulfilled by this variant. Interestingly, in some
reports also hint at a role for CtBP as a tumor promoter.
The data generated in this study on the functional role of
CtBP1-regulated genes suggest an implication in migra-
tory and invasive processes. It, therefore, appears that loss
of the CtBP1 co-repressor function may be a critical event
in the pathogenesis of melanoma, however, important
tumor promoting effects of CtBP can be achieved by
CtBP1splice.
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